跳至主要内容
临床试验/NCT01013272
NCT01013272已完成不适用

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

The University of Hong Kong1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
1
主要终点
Determine the efficacy of lamivudine therapy in patients with prior entecavir treatment with undetectable viral load

研究概览

简要总结

Patients with chronic hepatitis B and treated with entecavir for over 6 months (with no previous other antiviral treatment) will be invited to participate in this study. They will be eligible if their liver tests are normal and their viral load is undetectable. Patients will be switched to lamivudine treatment to assess whether lamivudine can maintain adequate suppression of the hepatitis B virus after successful treatment with entecavir. Patients will be monitored closely after switching treatment at 1 months and then every 3 monthly. If there is any evidence of increase in viral load then patients will be given the option of changing back to entecavir.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with chronic hepatitis B treated with entecavir for 6 months or more
  • Normal ALT
  • Undetectable HBV DNA by Roche Taqman PCR Assay
  • No other previous therapy with nucleoside/nucleotide analogues

排除标准

  • Presence of other liver diseases including hepatitis C co-infection, autoimmune hepatitis , primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and Wilson's disease
  • History of hepatocellular carcinoma
  • History of decompensated liver disease

研究组 & 干预措施

Entecavir

Active Comparator

Ongoing entecavir 0.5mg daily

干预措施: Entecavir (Drug)

Lamivudine

Active Comparator

Switch to lamivudine 100mg daily

干预措施: Lamivudine (Drug)

结局指标

主要结局

Determine the efficacy of lamivudine therapy in patients with prior entecavir treatment with undetectable viral load

时间窗: 96 weeks

次要结局

  • Determine the chance of lamivudine resistance in patients with prior entecavir treatment with undetectable viral load(96 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

James Yan Yue Fung

Dr

The University of Hong Kong

研究点 (1)

Loading locations...

相似试验